Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

27 Apr 2024

Abstract excerpt

Immune checkpoint blockade therapy aims to activate the immune system to eliminate cancer cells. However, clinical benefits are only recorded in a subset of patients. Here, we leverage genome-wide CRISPR/Cas9 screens in a Tumor-Immune co-Culture System focusing on triple-negative breast cancer (TNBC). We reveal that NEDD8 loss in cancer cells causes a vulnerability to nivolumab (anti-PD-1). Genetic deletion of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to RNA modifications and cancer
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38678024
DOI: 10.1038/s41467-024-47987-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancerPMID 38678024Read ↗

NEDD8 loss causes cancer vulnerability to immune checkpoint blockade in triple-negative breast cancerSemantic proximity Read ↗

In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancerSemantic proximity Read ↗

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeuticsSemantic proximity Read ↗

Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasionSemantic proximity Read ↗

Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer ResearchSemantic proximity Read ↗

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and TherapySemantic proximity Read ↗

<i>In Vivo</i> CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy TargetSemantic proximity Read ↗

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.Semantic proximity Read ↗

The Cul5 E3 Ligase Complex Is a Key Negative Feedback Regulator of TCR/IL2 Signaling and Anti-Tumor Activity in CD8 <sup>+</sup> T CellsSemantic proximity Read ↗

Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapySemantic proximity Read ↗

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapySemantic proximity Read ↗

Querying functional drivers in primary murine naïve and memory T cells using RNP-mediated CRISPR-Cas9 Gene DeletionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.